Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients

Pharmacogenetics

Volumn 7, Issue 5, 1997, Pages 415-418

  Suzuki, Akihito ^a   Otani, Koichi ^b   Mihara, Kazuo ^a   Yasui, Norio ^a   Kaneko, Sunao ^a   Inoue, Yoshimasa ^b   Hayashi, Kunihiko ^c  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c Pharmaceutical Technology Center   (Japan)

Author keywords

CYP2D6 genotype; Haloperidol; Reduced haloperidol; Steady state plasma

Indexed keywords

CYTOCHROME P450 ISOENZYME; HALOPERIDOL; REDUCED HALOPERIDOL;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SHORT SURVEY;

ADULT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HALOPERIDOL; HETEROZYGOTE; HOMOZYGOTE; HUMANS; JAPAN; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 0030826785     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199710000-00013     Document Type: Short Survey

References (19)

1. Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, Black B, Shader RI. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry 1986: 143, 650-651.
2. Bertilsson L, Dahl ML. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996: 5, 200-223.
3. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991: 10, 545-558.
4. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, Shoaf S, Egan M, Elkashef A, Liboff S, Linnoila M. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994: 14, 340-343.
5. Eyles DW, McGrath JJ, Pond SM. Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology 1996: 125, 214-219.
6. Gram LF, Debruyne D, Caillard V, Boulenger JP, Lacotte J, Moulin M, Zarifian E. Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 1989: 27, 272-275.
7. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990: 336, 529-532.
8. Hikida K, Inoue Y, Miyazaki T, Kojima N, Ohkura Y. Determination of bromperidol in serum by automated column-switching high performance liquid chromatography. J Chromatogr 1989: 495, 227-234.
9. Inaba T, Jurima M, Mahon WA, Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Disp 1985: 13, 443-448.
10. Jann MW, Lam WFF, Chang WH. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. Psychopharmacology 1990: 101, 107-111.
11. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994: 46, 452-459.
12. Linnoila M, Viukari M, Vaisanen K, Auvinen J. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry 1980: 137, 819-821.
13. LLerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992a: 14, 92-97.
14. LLerena A, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992b: 14, 261-264.
15. Nyberg S, Farde L, Halldin C, Dahl ML, Bertilsson L. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995: 152, 173-178.
16. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996: 6, 441-447.
17. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idre JR, Gulbrandsen AK. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995: 5, 215-223.
18. Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol 1994: 14, 159-162.
19. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/ debrisoquine monooxygenase). Br J Clin Pharmacol 1991: 31, 655-660.